Patient resting in a hospital bed

NIHR to investigate new potential Covid-19 treatment

A potential new treatment for hospitalised Covid-19 patients, using an anti-inflammatory arthritis drug, is being investigated by the NIHR-supported RECOVERY trial.

As an anti-inflammatory drug, baricitinib could potentially block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state caused by severe Covid-19 infections.

The researchers will investigate whether the drug reduces the risk of death for patients with Covid-19, whether the treatment reduces hospital stay lengths and whether it can reduce the risk of hospitalised patients requiring mechanical ventilation.

The trial will randomise 2,500 participants to receive baricitinib - with those results then compared against a further 2,500 participants receiving only standard care.

Professor Martin Landray, co-Chief Investigator for the RECOVERY trial from the University of Oxford, said: “Inflammation is a fundamental feature of Covid-19 and the RECOVERY trial has already found that one anti-inflammatory drug, dexamethasone, can reduce deaths in the most severely ill patients with Covid-19.

“Baricitinib is widely used to treat rheumatoid arthritis.

“By including baricitinib in the RECOVERY trial, we will be able to generate robust evidence on whether it helps tackle the worst consequences of Covid-19.”

Professor Peter Horby, co-Chief Investigator, added: “Baricitinib will be the tenth potential Covid-19 treatment to be tested through RECOVERY and we will continue testing new drugs as fast as we possibly can.”

Another arthritis drug treatment, tocilizumab and a second drug called sarilumab, also showed positive signs in improving intensive care Covid-19 patients, as part of the separate REMAP-CAP clinical trial.

NHE July/August 21

NHE July/August 21

Prioritising staff wellbeing

NHE’s July/August 2021 edition focuses on some of the key, defining aspects of a successful, supported health service: Mental Health & Workforce. Elsewhere, we take on the incredibly topical Infection Prevention and address the role which Pharma will play in both our NHS and wider health environment.

Videos...

View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Festival: Digital Healthcare

The integration of new technology, such as using virtual outpatient appointments instead of face-to-face reviews of patients in the hospital. Adapting the ways in which our NHS workers serve people has been critical in continuing to provide high-quality treatment, a positive patient experience and preventing Covid-19 transmission during the pandemic. Our healthcare sector has the potential to transform the way we continue to provide essential services while also improving patient care. But how easy is the integration of these innovations into routine NHS practice?

On the 28th of October, at the NHE365 Virtual Hospitals & Technology Enabled Care online event, we will be discussing patient flow and experience, reducing waiting times, reducing the patient backlog and increasing technology adoption. Will you be attending? 

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all